News

Roger A. Goldberg, MD, MBA, speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that small misalignments in the plunger can lead to possible overdosing.

Felipe Medeiros, MD, in a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that a phase 3 clinical extension study of the bimatoprost implant found that patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fields.

Shady Awwad, MD, in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.

tPA treatment could provide benefits for patients with central retinal artery occlusion.

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dilsher Dhoot, MD, reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular edema.

John B. Miller, MD, discusses widefield swept-source OCTA and its use in monitoring biomarkers in diabetic retinopathy.

Ash Abbey, MD, discusses the COED trial, testing the efficacy of combining steroid and anti-VEGF therapy in patients with diabetic macular edema.

Results from our recent poll regarding AAO 2021 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in-person.

At ASRS, David Brown, MD, reported positive results at the head-to-head endpoints of KESTREL and KITE, but with continuing concerns about inflammation.

Organizations are urging consumers to be aware of insurance policies that can limit their access to sight-saving procedures and treatments.

Two photographs are selected by an independent panel of five judges for this year’s honors.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia.

Dr. Jorge Calzada shares his methods for treating diabetic macular edema with MicroPulse Laser and anti-VEGF injections.

Confronting issues unique to aging may lead to better outcomes.

Nathan Steinle, MD, discusses top-line results of the OAKS and DERBY trials, testing the efficacy of pegcetacoplan for the treatment of geographic atrophy.

A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.

The Cleveland Clinic named Rishi Singh, MD, president of the Cleveland Clinic Martin North and South hospitals in Martin County, Florida.

Carl Regillo, MD, takes us through the history of the port delivery system, from ideation to FDA approval.

The Academy's annual meeting is set for November 12 to 15 in New Orleans.

The investigators reported the following most prominent cognitive deficits: processing speed, executive functioning, and phonemic fluency among others.

XIPERE, the first therapy utilizing the suprachoroidal space, demonstrates rapid efficacy, durable benefit, and favorable safety profile.

Susvimo, previously called the Port Delivery System with ranibizumab, is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.

Dr. Victor Gonzalez discusses his presentation at ASRS, regarding 0.19mg fluocinolone acetonide implants in diabetic macular edema (DME) patients.

A poll for retina specialists regarding their attendance at the 2021 American Academy of Ophthalmology Meeting in New Orleans, Louisiana. This poll is now closed.

Nimesh Patel, MD, discusses his presentation entitled, "Scleral-Sutured Intraocular Lens Dislocations Secondary to Eyelet Fractures" at ASRS.

Luminopia One is one of few digital therapeutics to receive FDA approval via the de novo pathway, and it is the first for amblyopia, and for a neuro-visual disorder in general.

Investigators find that long-term ocular complications require further observation.

The development-stage biotechnology company Omega Therapeutics is teaming up with Stanford University to investigate therapies for ocular diseases via control of specific ocular disease genes.

On October 14, we celebrate World Sight Day by pledging to receive annual eye exams, preventing or slowing vision loss, and showing love for our eyes.